Lymphotoxin-alpha (LT-alpha) (LT-alpha3)

Lymphotoxin-alpha (LT-alpha), specifically in its homotrimeric form LT-alpha3, is a secreted cytokine belonging to the tumor necrosis factor (TNF) superfamily [UniProt P01374]. It is primarily produced by activated T and B lymphocytes and plays a pivotal role in the development and maintenance of secondary lymphoid organs, such as lymph nodes and Peyer's patches [PubMed: 10591238]. LT-alpha3 signals through the receptors TNFR1, TNFR2, and HVEM, mediating pro-inflammatory responses and apoptosis [NCBI Gene: 4049]. Unlike the membrane-bound LT-alpha/beta heterotrimer, LT-alpha3 acts as a soluble ligand that can exert systemic effects [PubMed: 15771581]. In pathological states, overproduction of LT-alpha3 is linked to chronic inflammatory and autoimmune diseases, including rheumatoid arthritis and multiple sclerosis [PubMed: 22407918]. It has also been implicated in the formation of tertiary lymphoid structures in cancer and chronic infection [PubMed: 28630091]. Therapeutic targeting of LT-alpha3 aims to mitigate tissue damage and systemic inflammation by blocking its interaction with its cognate receptors. Drugs such as etanercept, a soluble TNFR2-Fc fusion protein, bind and neutralize LT-alpha3 in addition to TNF-alpha [DrugBank: DB00005]. Monoclonal antibodies like pateclizumab have also been investigated for their ability to specifically target LT-alpha in autoimmune conditions [ClinicalTrials.gov: NCT00744107]. Understanding the distinct roles of LT-alpha3 versus other TNF family members is crucial for developing more selective and effective immunotherapies.

Other names

Tumor necrosis factor-betaTNF-betaTumor necrosis factor ligand superfamily member 1TNFSF1LT-alpha3LT-alpha

Neutralization of soluble LT-alpha3 prevents its binding to TNFR1, TNFR2, and HVEM receptors, thereby inhibiting downstream pro-inflammatory signaling pathways.